China Biologic Products Holdings Inc (CBPO) Stake Lessened by Myriad Asset Management Ltd.

Myriad Asset Management Ltd. cut its holdings in shares of China Biologic Products Holdings Inc (NASDAQ:CBPO) by 38.7% during the first quarter, HoldingsChannel reports. The firm owned 52,349 shares of the biopharmaceutical company’s stock after selling 33,087 shares during the period. Myriad Asset Management Ltd.’s holdings in China Biologic Products were worth $4,776,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of CBPO. Hillhouse Capital Advisors Ltd. acquired a new position in shares of China Biologic Products during the fourth quarter worth $208,844,000. Norges Bank purchased a new stake in shares of China Biologic Products during the fourth quarter valued at $23,082,000. FMR LLC grew its holdings in shares of China Biologic Products by 64.6% during the fourth quarter. FMR LLC now owns 737,579 shares of the biopharmaceutical company’s stock valued at $55,990,000 after buying an additional 289,485 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of China Biologic Products by 11.6% during the third quarter. Vanguard Group Inc now owns 873,552 shares of the biopharmaceutical company’s stock valued at $69,884,000 after buying an additional 90,532 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of China Biologic Products by 11.6% during the third quarter. Vanguard Group Inc. now owns 873,552 shares of the biopharmaceutical company’s stock valued at $69,884,000 after buying an additional 90,532 shares during the last quarter. 37.31% of the stock is currently owned by institutional investors and hedge funds.

Shares of CBPO traded down $0.19 during trading hours on Wednesday, reaching $92.56. 8,106 shares of the company traded hands, compared to its average volume of 277,371. The firm has a market capitalization of $3.63 billion, a PE ratio of 23.05, a price-to-earnings-growth ratio of 4.89 and a beta of 1.28. China Biologic Products Holdings Inc has a 12-month low of $60.08 and a 12-month high of $107.44.



China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. China Biologic Products had a net margin of 27.71% and a return on equity of 8.81%. The firm had revenue of $129.78 million for the quarter, compared to analyst estimates of $119.50 million. During the same period in the previous year, the company earned $1.21 earnings per share. On average, equities research analysts forecast that China Biologic Products Holdings Inc will post 3.78 EPS for the current fiscal year.

A number of equities research analysts have recently weighed in on CBPO shares. ValuEngine raised shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Credit Suisse Group set a $88.00 price objective on shares of China Biologic Products and gave the company a “hold” rating in a report on Friday, March 8th. Jefferies Financial Group lowered shares of China Biologic Products from a “hold” rating to an “underperform” rating and dropped their price objective for the company from $67.00 to $62.00 in a report on Monday, March 11th. BidaskClub raised shares of China Biologic Products from a “hold” rating to a “buy” rating in a report on Friday, April 5th. Finally, Zacks Investment Research raised shares of China Biologic Products from a “strong sell” rating to a “hold” rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. China Biologic Products presently has a consensus rating of “Hold” and a consensus price target of $78.00.

COPYRIGHT VIOLATION WARNING: “China Biologic Products Holdings Inc (CBPO) Stake Lessened by Myriad Asset Management Ltd.” was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://dakotafinancialnews.com/2019/05/15/china-biologic-products-holdings-inc-cbpo-stake-lessened-by-myriad-asset-management-ltd.html.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

See Also: What are economic reports?

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings Inc (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.